Back

Antithrombotic therapy in patients with atrial fibrillation and a so-called temporary cause: a different benefit in case of acute coronary syndrome?

19 March 2018 (15:35 - 16:25)
Organised by:
Congress Presentation Part of: Managing the thromboembolic risk in atrial fibrillation Atrial Fibrillation - Stroke Prevention - Oral Anticoagulation EHRA Premium Access EHRA 2018

About the speaker

Photo
Professor Arnaud Bisson

CHU de Tours, Tours (France)

6 More presentations in this session

Presentation thumbnail
Incidence of atrial arrhythmia and uptake of anticoagulation in stroke and non-stroke populations according to arrhythmia burden; a 7-year experience.
Doctor P. Chousou (Cambridge, GB)
Abstract Slides
Presentation thumbnail
Relation of Nonsteroidal Anti-Inflammatory Drugs and Time in Therapeutic Range in Bleeding Risk in Atrial Fibrillation: the SPORTIF Trials
Doctor M. Proietti (Milan, IT)
Abstract Slides
Presentation thumbnail
Incidence and predictors of left atrial appendage thrombus in patients treated with direct oral anticoagulants versus warfarin for non-valvular atrial fibrillation
Doctor K. Minami (Utsunomiya, JP)
Abstract Slides
Presentation thumbnail
Left atrial stunning as a predictor of atrial fibrillation occurrence after cryptogenic stroke
Doctor J. Farinha (Setubal, PT)
Abstract Slides
Presentation thumbnail
Indications for and outcome in patients undergoing left atrial appendage closure - Results of the Austrian LAAC Registry
Mr D. Zweiker (Vienna, AT)
Abstract Slides

Access the full session

Session thumbnail
Managing the thromboembolic risk in atrial fibrillation

The Event

Event poster

EHRA 2018

19 March 2018 15:35 CET
You may be interested in
thumbnail
Congress Presentation
Anticoagulation in patients with new-onset atrial fibrillation after acute coronary syndrome
29 June 2021
thumbnail
Webinar
Balancing stroke and bleeding risks in patients with AF and concomitant coronary artery disease, malignancy, chronic kidney disease, or frailty
10 November 2025
thumbnail
Congress Presentation
Atrial fibrillation: the difference in thromboembolic events prognosis
19 March 2022
thumbnail
Congress Presentation
Non valvular atrial fibrillation, contraindication to anticoagulation or antiplatelet therapy and heart team approach: a single centre experience
2 September 2019

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources